These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26957610)

  • 41. Carcinoid tumour management in haemodialysis: a case report.
    Burke MT; Gray NA
    Nephrology (Carlton); 2012 Feb; 17(2):198. PubMed ID: 22257155
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
    Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
    Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
    Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Medical treatment of digestive neuroendocrine tumours].
    Panzuto F; Nasoni S; Delle Fave G
    Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. When and How to Use Somatostatin Analogues.
    de Herder WW
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):549-555. PubMed ID: 30098715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.
    Scherübl H; Wiedenmann B; Riecken EO; Thomas F; Böhme E; Räth U
    Eur J Cancer; 1994; 30A(10):1590-1. PubMed ID: 7833124
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
    Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
    N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
    [No Abstract]   [Full Text] [Related]  

  • 49. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
    Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
    Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of somatostatin analogues for the detection and treatment of gastrinoma in a dog.
    Altschul M; Simpson KW; Dykes NL; Mauldin EA; Reubi JC; Cummings JF
    J Small Anim Pract; 1997 Jul; 38(7):286-91. PubMed ID: 9239629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.
    Eriksson B; Janson ET; Bax ND; Mignon M; Morant R; Opolon P; Rougier P; Oberg KE
    Digestion; 1996; 57 Suppl 1():77-80. PubMed ID: 8813476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
    Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
    Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
    Losa M; Mortini P; Giovanelli M
    Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcatheter valve implantation to inferior vena cava to control carcinoid symptoms.
    Sagar VM; Steeds RP; Doshi SN; Shah T
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract]   [Full Text] [Related]  

  • 59. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil.
    Valentim J; Passos V; Mataveli F; Calabró A
    Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1452-60. PubMed ID: 19197453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.